Vistagen Therapeutics (VTGN) Revenue (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Revenue of $465000.0 for Q1 2026, up 53.47% sequentially from $303000.0 in Q4 2025, and up 3200.0% YoY from $14090.9 in Q1 2025.
Vistagen Therapeutics (VTGN) Revenue (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Revenue for 10 years, with the latest figure at $465000.0 in Q1 2026.
- Quarterly Revenue rose 3200.0% year-over-year to $465000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 161.32% YoY) and the FY2026 annual result came in at $1.3 million, up 161.11% from the prior year.
- Revenue advanced to $465000.0 in Q1 2026 per VTGN's latest filing, from $303000.0 in the prior quarter.
- Over five years, Revenue peaked at $893000.0 in Q3 2022 and troughed at -$15000.0 in Q1 2025.
- A 5-year average of $262476.5 and a median of $234000.0 in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2025 and 2026: Revenue sank 107.61% in 2025, then surged 3200.0% in 2026.
- Over 5 years, Revenue stood at $180000.0 in 2022, then jumped by 128.33% to $411000.0 in 2023, then tumbled by 43.07% to $234000.0 in 2024, then grew by 29.49% to $303000.0 in 2025, then soared by 53.47% to $465000.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $465000.0, $303000.0, and $258000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | 1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 465,000.00 |
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 258,000.00 |
| Jun 30, 2025 | 244,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | 234,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Jun 30, 2024 | 84,000.00 |
| Mar 31, 2024 | 197,000.00 |
| Dec 31, 2023 | 411,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 176,000.00 |
| Dec 31, 2022 | 180,000.00 |
| Sep 30, 2022 | 893,000.00 |
| Jun 30, 2022 | 310,100.00 |
| Mar 31, 2022 | 39,000.00 |
| Dec 31, 2021 | 358,000.00 |
| Sep 30, 2021 | 358,000.00 |
| Jun 30, 2021 | 354,000.00 |